Methods and uses thereof of prosaposin
AssigneeChildren's Medical Center Corporation
InventorRandolph Watnick
Life of this patent
Estimating the term…
Loading patent…
AssigneeChildren's Medical Center Corporation
InventorRandolph Watnick
Estimating the term…
The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and/or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor/cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti-angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastatic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development.
A method of treating an angiogenesis-dependent disease or disorder, comprising administering to a subject in need of treatment thereof, a therapeutically effective amount of Psap protein or a vector comprising a nucleic acid encoding Psap protein and a pharmaceutically acceptable carrier.
A method of inhibiting the recurrence of an angiogenesis-dependent disease or disorder, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
A method of inhibiting metastasis of cancer in a subject diagnosed with cancer, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
A method for prognostic evaluation of an individual diagnosed with cancer comprising:
A method of treating an individual diagnosed with cancer comprising:
A method of screening and identifying tumor secreted factors that promote angiogenesis and metastasis comprising:
A method of predicting the metastatic tissue specificity of cancer cells in an individual diagnosed with cancer comprising:
A method for determining the likelihood of metastasis an individual diagnosed with cancer comprising:
An isolated chimeric polypeptide comprising a first portion and a second portion, wherein said first portion is saposin A (SEQ. ID. No. 13) or a functional fragment thereof, and said second portion wherein said second portion is not a Psap protein, and wherein said first portion is capable of activating p53 and inducing Tsp-1 expression.
A composition comprising of a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
A method of treating an angiogenesis-dependent disease or disorder, comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising of a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.